One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab

Ravulizumab every 8 weeks showed non‐inferiority to eculizumab every 2 weeks in a 26‐week, phase 3, randomized controlled trial in adults with paroxysmal nocturnal hemoglobinuria (PNH) who were clinically stable on eculizumab (NCT03056040). We report results from the first 26 weeks of the extension...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Haematol
Autors principals: Kulasekararaj, Austin G., Hill, Anita, Langemeijer, Saskia, Wells, Richard, González Fernández, F. Ataúlfo, Gaya, Anna, Ojeda Gutierrez, Emilio, Piatek, Caroline I., Mitchell, Lindsay, Usuki, Kensuke, Bosi, Alberto, Brodsky, Robert A., Ogawa, Masayo, Yu, Ji, Ortiz, Stephan, Röth, Alexander, Lee, Jong Wook, Peffault de Latour, Régis
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2021
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8246907/
https://ncbi.nlm.nih.gov/pubmed/33301613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13564
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars